8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 31, 2010

BIOMET, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

Indiana	001-15601	35-1418342
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

56 East Bell Drive

Warsaw, Indiana 46582

(Address of Principal Executive Offices, Including Zip Code)

(574) 267-6639

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On January 6, 2011, the Company issued a press release with respect to results for the second fiscal quarter of fiscal 2011. The press release attached hereto as Exhibit 99.1 is incorporated by reference herein.

The earnings release attached as Exhibit 99.1 includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP. Management exercises judgment in determining which types of charges or other items should be excluded from non-GAAP measures. Management uses this non-GAAP information internally to evaluate the performance of the core operations, establish operational goals and forecasts that are used in allocating resources and to evaluate the Company’s performance period over period. Additionally, Biomet’s management is evaluated on the basis of some of these non-GAAP financial measures when determining achievement of their incentive compensation performance targets. The Company believes that its disclosure of these non-GAAP financial measures provides investors greater transparency to the information used by Biomet management for its financial and operational decision-making and enables investors to better understand the Company’s period-to-period operating performance.

The non-GAAP financial measures included in the press release consist of net sales excluding the impact of foreign currency (constant currency), operating income as adjusted, net income as adjusted, free cash flow, unlevered free cash flow, net debt, Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), Adjusted EBITDA (as defined by our credit agreement, the method to calculate this is likely to be different from methods used by other companies), gross profit as adjusted, selling, general and administrative expense as adjusted, research and development expense as adjusted, senior secured leverage ratio, total leverage ratio and total leverage ratio (net debt). Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included elsewhere in the press release.

The term “as adjusted,” a non-GAAP financial measure, refers to financial performance measures that exclude certain income statement line items, such as interest, taxes, depreciation or amortization and/or exclude certain expenses as defined by our credit agreement, such as restructuring charges, non-cash impairment charges, integration and facilities opening costs or other business optimization expenses, new systems design and implementation costs, certain start-up costs and costs related to consolidation of facilities, certain non-cash charges, advisory fees paid to the private equity owners, certain severance charges, purchase accounting costs, stock-based compensation and payments, litigation costs, and other related charges.

The leverage ratios provide a measure of the Company’s financial ability to meet its debt service obligations. The Company believes these ratios provide valuable insight to understanding how Biomet management manages its operations and financial position with respect to its debt obligations.

The following is an explanation of each of the items, as permitted by our credit agreement that management excluded from one or more of the non-GAAP financial measures used in this press release and the reasons for excluding each of these items:

Impact of Foreign Currency. The Company excludes the foreign currency impact on net sales information compared to prior year results primarily because it is not reflective of the ongoing operating results and is not used by management in evaluation of net sales performance. The Company further believes this information is useful to investors in that it provides period over period comparability. The impact of foreign currency exchange rates is calculated by translating actual current period net sales at the prior year exchange rate. These results are used to determine year-over-year percentage increase or decrease that excludes the impact of changes in foreign currency exchange rates.

Purchase Accounting Depreciation and Amortization. Depreciation and amortization related to the Merger are excluded in non-GAAP measures as they are not reflective of the Company’s ongoing operational performance or liquidity. The Company further believes the exclusion of this information in the applicable non-GAAP financial measure is useful to investors in that it provides period over period comparability.

Share-Based Payment. Stock-based compensation expense is excluded from non-GAAP measures primarily because it is a non-cash expense. The Company further believes that excluding this item is useful to investors in that it facilitates comparisons to competitors’ operating results.

Litigation Settlements and Reserves and Other Legal Fees. The Company excludes litigation related expenses from non-GAAP measures that are not reflective of the Company’s ongoing operational performance. The Company further believes this information is useful to investors in that it provides period over period comparability.

Operational Restructuring and Consulting Expenses Related to Operational Improvement Initiatives. Restructuring charges relate principally to employee severance and facility consolidation costs resulting from the closure of facilities and other workforce reductions attributable to our efforts to reduce costs. Operational restructuring charges also include abnormal manufacturing variances related to temporary redundant overhead costs within the Company’s plant network as the Company continues to rationalize and move production to its larger operating locations in order to increase manufacturing efficiency. The Company excludes these costs from non-GAAP measures primarily because they are not reflective of the ongoing operating results and they are not used by management to assess ongoing operational performance. The Company further believes the exclusion of this information in the applicable non-GAAP financial measure is useful to investors in that it provides period over period comparability.

Sponsor Fee. Upon completion of the Merger, the Company entered into a management services agreement with certain affiliates of the Sponsors, pursuant to which such affiliates of the Sponsors or their successors assigns, affiliates, officers, employees, and/or representatives and third parties (collectively, the “Managers”) provide management, advisory, and consulting services to the Company. Pursuant to such agreement, the Managers received a transaction fee equal to 1% of total enterprise value of the Transactions for the services rendered by such entities related to the Transactions upon entering into the agreement, and the Sponsors receive an annual monitoring fee equal to 1% of the Company’s annual Adjusted EBITDA (as defined in our credit agreement) as compensation for the services rendered and reimbursement for out-of-pocket expenses incurred by the Managers in connection with the agreement and the Transactions. The Company excludes these costs from non-GAAP measures primarily because they are not reflective of the ongoing operating results and they are not used by management to assess ongoing operational performance. The Company further believes the exclusion of this information in the applicable non-GAAP financial measure is useful to investors in that it provides period over period comparability.

The following is an explanation of each of the other items that management excluded from one or more of the non-GAAP financial measures used in this press release and the reasons for excluding each of these items:

Tax Effect on Special and Purchase Accounting Items. This amount is used to present the impact of the above non-GAAP adjustments on net income, as adjusted.

Net Debt. Net debt is the sum of the Company’s total debt less cash and cash equivalents and short-term investments. The Company believes net debt provides a useful measure of the Company’s liquidity and overall debt position.

The Company is furnishing the information contained in Item 2.02 of this report, including the press release attached hereto as Exhibit 99.1, pursuant to Item 2.02 of Form 8-K promulgated by the Securities and Exchange Commission (the “SEC”). This information shall not be deemed to be “filed” with the SEC or incorporated by reference into any other filing with the SEC.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) On December 31, 2010, the Board of Directors and stockholders of the Company’s parent company, LVB Acquisition, Inc. (“Parent”), approved and adopted Amendment No. 1 (the “Amendment”) to LVB Acquisition, Inc. Management Equity Incentive Plan (the “Plan”). The Amendment increased the maximum number of shares of common stock, par value $0.01 per share, of Parent that may be issued under the Plan by 1,000,000 shares to an aggregate of 38,520,000 shares available for issuance under the Plan. The Amendment is being filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.	Document
10.1	Amendment No. 1 to LVB Acquisition, Inc. Management Equity Incentive Plan
99.1	Press Release issued January 6, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 6, 2011

BIOMET, INC.
	/S/    BRADLEY J. TANDY
By:	Bradley J. Tandy
Its:	Senior Vice President, General Counsel and Secretary

EX-10.1

Exhibit 10.1

AMENDMENT NO. 1 TO

LVB ACQUISITION, INC.

MANAGEMENT EQUITY INCENTIVE PLAN

Adopted December 31, 2010 (the “Effective Date”)

Section 4 of the LVB Acquisition, Inc. Management Equity Incentive Plan (the “Plan”) shall hereby be amended by deleting the first sentence of the preamble paragraph of Section 4 in its entirety and replacing it with the following:

Subject to adjustment as provided in Section 4.13 hereof, the Board may grant to Participants Options to purchase shares of Common Stock of the Company that, in the aggregate, do not exceed 38,520,000 shares of Common Stock for all Plan Participants.

EX-99.1

Exhibit 99.1

BIOMET ANNOUNCES SECOND QUARTER OF FISCAL YEAR 2011 FINANCIAL RESULTS

WARSAW, Ind., January 6, 2011 – Biomet, Inc. announced today financial results for its second fiscal quarter ended November 30, 2010.

• Reconstructive sales increased 1% (3% constant currency) worldwide and increased 3% in the U.S.

• Knee sales increased 2% (3% constant currency) worldwide, with U.S. growth of 3%

• Extremity sales grew 21% (23% constant currency) worldwide and increased at a rate of 36% in the U.S.

• Sports medicine sales increased 16% (17% constant currency) worldwide, with 17% U.S. growth

Second Quarter Financial Results

Net sales during the second quarter of fiscal year 2011 were flat at $698.3 million compared to net sales during the second quarter of fiscal year 2010 of $695.6 million. Excluding the effect of foreign currency, net sales increased 2% during the second quarter. U.S. net sales increased 2% to $416.9 million during the second quarter of fiscal 2011, while Europe net sales decreased 8% (decreased 1% at constant currency) to $188.8 million and International (primarily Canada, South America, Mexico and the Pacific Rim) net sales increased 12% (7% constant currency) to $92.6 million.

Special items (pre-tax) totaled $115.3 million during the second quarter, which included $96.9 million of non-cash amortization and depreciation expense related to the Merger and $18.4 million of non-Merger related special items.

On a reported basis, operating income was $105.8 million for the second quarter of fiscal year 2011 compared to operating income of $94.1 million for the second quarter of fiscal year 2010. Excluding special items in both periods, adjusted operating income was flat at $221.1 million.

Reported net loss for the second quarter of fiscal year 2011 was $7.6 million compared to a net loss of $7.2 million for the second quarter of fiscal year 2010. Excluding special items in both periods, adjusted net income for the second quarter totaled $66.0 million compared to adjusted net income of $74.8 million in the prior year period.

Excluding special items, adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) for the second quarter was $263.7 million, or 37.8% of net sales, compared to adjusted EBITDA for the second quarter of fiscal year 2010 of $265.4 million.

Interest expense was $122.9 million during the second quarter of fiscal year 2011 compared to $130.1 million during the second quarter of the prior year, principally due to lower interest rates on floating rate debt.

Reported cash flow from operations was $20.1 million during the second quarter of fiscal year 2011, while free cash flow (operating cash flow of $20.1 million minus capital expenditures of $52.3 million) was a use of cash of $32.2 million, reflecting $195 million of cash interest paid in the quarter. Unlevered free cash flow (cash flow before debt service) totaled $168.3 million for the second quarter of fiscal year 2011 compared to $165.1 million in the prior year period.

Reported gross debt was $5.946 billion as of November 30, 2010, and cash on hand was approximately $229 million, which resulted in net debt of $5.717 billion. From May 31, 2008, the first fiscal year-end after the Merger, to November 30, 2010, net debt decreased by $456 million as a result of an increase in cash of $101 million and a $355 million reduction of gross debt, including a $202 million decrease due to favorable foreign currency translation on the Company’s Euro-denominated debt.

The Company’s senior secured leverage ratio at November 30, 2010 was 3.41 times the last twelve months (“LTM”) adjusted EBITDA (as defined in the Company’s Credit Agreement dated September 25, 2007) compared to 4.16 times at May 31, 2008. The net debt leverage ratio at November 30, 2010 was 5.74 times LTM adjusted EBITDA compared to 6.97 times at May 31, 2008.

Biomet’s President and Chief Executive Officer Jeffrey R. Binder stated, “While consolidated net sales increased 2% at constant currency during our second fiscal quarter, we delivered a strong adjusted EBITDA margin of 37.8% of net sales. Additionally, I’m pleased with our operating cash flow for the first half of the year. We believe that market growth rates for orthopaedic reconstructive products continued to be depressed in the quarter. However, an improving economy, favorable demographics and product innovation should stimulate long-term market growth and we continue to make significant research and development investments to address unmet clinical needs across our business.”

A reconciliation of reported results to adjusted results is included in this press release, which is also posted on Biomet’s website: www.biomet.com

The following table provides second quarter net sales performance by product segment:

	Second Quarter Net Sales Performance
	Worldwide		Worldwide			Worldwide			United
	Reported		Reported			CC			States
	Quarter 2 - FY 2011		Growth %			Growth %			Growth %
Reconstructive	$	540.5		1	%		3	%		3	%
Orthopedic Reconstructive				1	%		3	%		3	%
Hips				(1	)%		—	%		—	%
Knees				2	%		3	%		3	%
Total Hips & Knees				1	%		2	%		2	%
Extremities				21	%		23	%		36	%
Other				(5	)%		(3	)%		(2	)%
Dental				1	%		3	%		(2	)%
Fixation		56.3		(3	)%		(2	)%		(1	)%
Spine		56.0		(3	)%		(3	)%		—	%
Other		45.5		—	%		2	%		2	%
Sports Medicine				16	%		17	%		17	%
Other				(16	)%		(14	)%		(16	)%
Total Sales	$	698.3		—	%		2	%		2	%

Reconstructive product sales increased 1% (3% constant currency) worldwide, with growth of 3% in the United States during the second quarter of fiscal year 2011. Knee sales increased 2% (3% constant currency) worldwide during the second quarter and increased 3% in the U.S. Sales of the Vanguard^® Complete Knee System, E1™ antioxidant infused tibial bearings and Regenerex^® porous titanium components were the key contributors to the Company’s second quarter knee sales.

Hip sales decreased 1% (flat at constant currency) worldwide during the second quarter and were flat in the U.S. Extremity sales increased 21% (23% constant currency) worldwide and grew at a rate of 36% in the U.S. during the second quarter. The Comprehensive^® Primary and Reverse Shoulder Systems continued to drive strong growth for the extremity product category.

Dental reconstructive device sales increased 1% worldwide (3% constant currency) during the second quarter of fiscal year 2011 and decreased 2% in the U.S.

Fixation sales decreased 3% (decreased 2% constant currency) worldwide and decreased 1% in the U.S. during the second quarter. Craniomaxillofacial fixation sales growth was more than offset by decreased sales of internal fixation, external fixation, and electrical stimulation devices.

Spine sales decreased 3% (decreased 3% constant currency) worldwide and were flat in the U.S. during the second quarter. Sales growth of spinal stimulation devices during the quarter was more than offset by decreased sales of spine hardware and orthobiologics.

Sales of “other” products were flat (increased 2% constant currency) worldwide and increased 2% in the U.S. during the second quarter. Sports medicine sales increased 16% (17% constant currency) worldwide and grew 17% in the U.S., while sales of softgoods and bracing products decreased during the second quarter. Continued strong sales of sports medicine products were primarily driven by increased demand for the JuggerKnot™ Soft Anchor, the ToggleLoc™ Femoral Fixation Device with ZipLoop™ Technology and the Maxfire™ MarXmen™ Meniscal Repair Device.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current presentation. Such reclassifications were limited to net sales information by product and geographical category. Specifically, for the three and six months ended November 30, 2010, the Company reclassified $5.8 million and $11.6 million from Other product net sales to Reconstructive product net sales, respectively, and $1.1 million and $2.3 million from Spine product net sales to Fixation product net sales, respectively. For the three and six months ended November 30, 2010, the Company also reclassified $1.2 million and $2.2 million from Europe net sales to International net sales, respectively. The current presentation aligns with how the Company presently manages and markets its products.

Financial Schedule Presentation

The Company’s unaudited condensed consolidated financial statements as of and for the three and six months ended November 30, 2010 and 2009 and other financial data included in this press release have been prepared in a manner that complies, in all material respects, with generally accepted accounting principles in the United States (except with respect to certain non-GAAP financial measures discussed below) and reflects purchase accounting adjustments related to the Merger referenced below.

About Biomet

Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet’s product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, autologous therapies and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in approximately 90 countries.

The Merger

Biomet, Inc. finalized the merger with LVB Acquisition Merger Sub, Inc., a wholly-owned subsidiary of LVB Acquisition, Inc., which we refer to in this press release as the “Merger”, on September 25, 2007. LVB Acquisition, Inc. is indirectly owned by investment partnerships directly or indirectly advised or managed by The Blackstone Group, Goldman Sachs & Co., Kohlberg Kravis Roberts & Co. and TPG Capital.

Contacts

For further information contact Daniel P. Florin, Senior Vice President and Chief Financial Officer, at (574) 372-1687 or Barbara Goslee, Director, Corporate Communications at (574) 372-1514.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements are often indicated by the use of words such as “will,” “intend,” “anticipate,” “estimate,” “expect,” “plan” and similar expressions. Forward-looking statements involve certain risks and uncertainties. Actual results may differ materially from those contemplated by the forward looking statements due to, among others, the following factors: the success of the Company’s principal product lines; the results of ongoing investigations by the United States Department of Justice and the United States Securities and Exchange Commission; the ability to successfully implement new technologies; the Company’s ability to sustain sales and earnings growth; the Company’s success in achieving timely approval or clearance of its products with domestic and foreign regulatory entities; the impact to the business as a result of compliance with federal, state and foreign governmental regulations and with the Corporate Integrity Agreement; the impact to the business as a result of the economic downturn in both foreign and domestic markets; the impact of federal health care reform; the impact of anticipated changes in the musculoskeletal industry and the ability of the Company to react to and capitalize on those changes; the ability of the Company to successfully implement its desired organizational changes and cost-saving initiatives; the impact to the business as a result of the Company’s significant international operations, including, among others, with respect to foreign currency fluctuations and the success of the Company’s transition of certain manufacturing operations to China; the impact of the Company’s managerial changes; the ability of the Company’s customers to receive adequate levels of reimbursement from third-party payors; the Company’s ability to maintain its existing intellectual property rights and obtain future intellectual property rights; the impact to the business as a result of cost containment efforts of group purchasing organizations; the Company’s ability to retain existing independent sales agents for its products; and other factors set forth in the Company’s filings with the SEC, including the Company’s most recent annual report on Form 10-K and quarterly report on Form 10-Q. Although the Company believes that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the

inherent uncertainties as to the occurrence or non-occurrence of future events. There can be no assurance as to the accuracy of forward-looking statements contained in this press release. The inclusion of a forward-looking statement herein should not be regarded as a representation by the Company that the Company’s objectives will be achieved. The Company undertakes no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements which speak only as of the date on which they were made.

*Non-GAAP Financial Measures:

Management uses non-GAAP financial measures, such as net sales excluding the impact of foreign currency (constant currency), operating income as adjusted, net income as adjusted, free cash flow, unlevered free cash flow, net debt, Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA (as defined by our credit agreement, the method to calculate this is likely to be different from methods used by other companies), gross profit as adjusted, selling, general and administrative expense as adjusted, research and development expense as adjusted, senior secured leverage ratio, total leverage ratio and total leverage ratio (net debt) as important financial measures to review and assess financial and operating performance of its principal lines of business. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included elsewhere in this press release.

The term “as adjusted,” a non-GAAP financial measure, refers to financial performance measures that exclude certain income statement line items, such as interest, taxes, depreciation or amortization and/or exclude certain expenses as defined by our credit agreement, such as restructuring charges, non-cash impairment charges, integration and facilities opening costs or other business optimization expenses, new systems design and implementation costs, certain start-up costs and costs related to consolidation of facilities, certain non-cash charges, advisory fees paid to the private equity owners, certain severance charges, purchase accounting costs, stock-based compensation and payments, litigation costs, and other related charges.

These non-GAAP measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States. Biomet management believes that these non-GAAP measures provide useful information to investors; however, this additional non-GAAP financial information is not meant to be considered in isolation or as a substitute for financial information prepared in accordance with GAAP.

Biomet, Inc.

Product Net Sales*

Three Month Period Ended November 30, 2010 and November 30, 2009

(in millions, unaudited)

	Three Months Ended November 30, 2010		Three Months Ended November 30, 2009		Reported Growth %			Constant Currency Growth %
Reconstructive	$	540.5	$	534.2		1	%		3	%
Fixation		56.3		58.1		(3	)%		(2	)%
Spine		56.0		57.8		(3	)%		(3	)%
Other		45.5		45.5		—	%		2	%
Net Sales	$	698.3	$	695.6		—	%		2	%

	Three Months Ended November  30, 2010 Net Sales Growth As Reported			Currency Impact			Three Months Ended November 30, 2010 Net Sales Growth in Local Currencies
Reconstructive		1	%		2	%		3	%
Orthopedic Reconstructive		1	%		2	%		3	%
Hips		(1	)%		1	%		—	%
Knees		2	%		1	%		3	%
Total Hips & Knees		1	%		1	%		2	%
Extremities		21	%		2	%		23	%
Other		(5	)%		2	%		(3	)%
Dental		1	%		2	%		3	%
Fixation		(3	)%		1	%		(2	)%
Spine		(3	)%		—	%		(3	)%
Other		—	%		2	%		2	%
Sports Medicine		16	%		1	%		17	%
Other		(16	)%		2	%		(14	)%
Total		—	%		2	%		2	%

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Product Net Sales*

Six Month Period Ended November 30, 2010 and November 30, 2009

(in millions, unaudited)

	Six Months Ended November 30, 2010		Six Months Ended November 30, 2009		Reported Growth %			Constant Currency Growth %
Reconstructive	$	1,018.9	$	1,002.8		2	%		3	%
Fixation		115.7		119.2		(3	)%		(2	)%
Spine		113.9		115.8		(2	)%		(1	)%
Other		90.5		87.9		3	%		5	%
Net Sales	$	1,339.0	$	1,325.7		1	%		2	%

	Six Months Ended November 30, 2010 Net Sales Growth As Reported			Currency Impact			Six Months Ended November 30, 2010 Net Sales Growth As Reported
Reconstructive		2	%		1	%		3	%
Orthopedic Reconstructive		2	%		1	%		3	%
Hips		—	%		1	%		1	%
Knees		3	%		1	%		4	%
Total Hips & Knees		1	%		2	%		3	%
Extremities		23	%		2	%		25	%
Other		(5)	%		2	%		(3)	%
Dental		(1)	%		2	%		1	%
Fixation		(3)	%		1	%		(2)	%
Spine		(2)	%		1	%		(1)	%
Other		3	%		2	%		5	%
Sports Medicine		15	%		2	%		17	%
Other		(10)	%		2	%		(8)	%
Total		1	%		1	%		2	%

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Geographic Segment Net Sales Percentage Summary*

Three Month Period Ended November 30, 2010 and November 30, 2009

(in millions, unaudited)

	Three Months Ended November 30, 2010		Three Months Ended November 30, 2009		Reported Growth %			Constant Currency Growth %
Geographic Segments:
United States	$	416.9	$	408.2		2	%		2	%
Europe		188.8		205.0		(8	)%		(1	)%
International		92.6		82.4		12	%		7	%
Net Sales	$	698.3	$	695.6		—	%		2	%

	Three Months Ended November 30, 2010 Net Sales Growth As Reported			Currency Impact			Three Months Ended November 30, 2010 Net Sales Growth Local Currencies
United States		2	%		—	%		2	%
Europe		(8	)%		7	%		(1	)%
International		12	%		(5	)%		7	%
Total		—	%		2	%		2	%

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Geographic Segment Net Sales Percentage Summary*

Six Month Period Ended November 30, 2010 and November 30, 2009

(in millions, unaudited)

	Six Months Ended November 30, 2010		Six Months Ended November 30, 2009		Reported Growth %			Constant Currency Growth %
Geographic Segments:
United States	$	836.0	$	808.3		3	%		3	%
Europe		326.0		358.8		(9	)%		(2	)%
International		177.0		158.6		12	%		6	%
Net Sales	$	1,339.0	$	1,325.7		1	%		2	%

	Six Months Ended November 30, 2010 Net Sales Growth As Reported			Currency Impact			Six Months Ended November 30, 2010 Net Sales Growth As Reported
United States		3	%		—	%		3	%
Europe		(9	)%		7	%		(2	)%
International		12	%		(6	)%		6	%
Total		1	%		1	%		2	%

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

As Reported Consolidated Statements of Operations

(in millions, unaudited)

	Three Months Ended			Three Months Ended
	November 30, 2010			November 30, 2009
Net sales	$	698.3		$	695.6
Cost of sales		207.5			213.6
Gross profit		490.8			482.0
Gross profit percentage		70.3	%		69.3	%
Selling, general and administrative expense		260.6			267.4
Research and development expense		29.6			25.2
Amortization		94.8			95.3
Operating income		105.8			94.1
Percentage of Net Sales		15.2	%		13.5	%
Other (income) expense		(3.9	)		(10.6	)
Interest expense		122.9			130.1
Loss before income taxes		(13.2	)		(25.4	)
Benefit from income taxes		(5.6	)		(18.2	)
Tax rate		42.4	%		71.7	%
Net loss	$	(7.6	)	$	(7.2	)
Percentage of Net Sales		-1.1	%		-1.0	%

Biomet, Inc.

As Reported Consolidated Statements of Operations

(in millions, unaudited)

	Six Months Ended November 30, 2010			Six Months Ended November 30, 2009
Net sales	$	1,339.0		$	1,325.7
Cost of sales		401.5			398.9
Gross profit		937.5			926.8
Gross profit percentage		70.0	%		69.9	%
Selling, general and administrative expense		512.5			513.4
Research and development expense		59.5			50.1
Amortization		190.0			190.1
Operating income		175.5			173.2
Percentage of Net Sales		13.1	%		13.1	%
Other (income) expense		(5.7	)		(14.9	)
Interest expense		249.7			261.6
Loss before income taxes		(68.5	)		(73.5	)
Benefit from income taxes		(43.1	)		(43.5	)
Tax rate		62.9	%		59.2	%
Net loss	$	(25.4	)	$	(30.0	)
Percentage of Net Sales		-1.9	%		-2.3	%

Biomet, Inc.

Other Financial Information

Operating Income, as reported to Operating Income, as adjusted

(in millions, unaudited)

	Three Months Ended November 30, 2010		Three Months Ended November 30, 2009
Operating income, as reported	$	105.8	$	94.1
Purchase accounting depreciation		4.4		4.4
Purchase accounting amortization		92.5		94.3
Total merger related depreciation and amortization		96.9		98.7
Share-based payment		4.3		4.3
Litigation settlements and reserves and other legal fees		3.1		3.5
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)		8.4		17.8
Sponsor fee		2.6		2.7
Total non-merger related items		18.4		28.3
Total items (pre-tax) excluded per our credit agreement		115.3		127.0
Operating income, as adjusted*	$	221.1	$	221.1

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Other Financial Information

Operating Income, as reported to Operating Income, as adjusted

(in millions, unaudited)

	Six Months Ended November 30, 2010		Six Months Ended November 30, 2009
Operating income, as reported	$	175.5	$	173.2
Purchase accounting depreciation		8.8		8.9
Purchase accounting amortization		184.9		188.2
Total merger related depreciation and amortization		193.7		197.1
Share-based payment		9.4		9.5
Litigation settlements and reserves and other legal fees		7.4		5.2
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)		17.7		23.3
Sponsor fee		4.9		4.9
Total non-merger related items		39.4		42.9
Total items (pre-tax) excluded per our credit agreement		233.1		240.0
Operating income, as adjusted*	$	408.6	$	413.2

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Other Financial Information

Net Loss to EBITDA, as reported

(in millions, unaudited)

	Three Months Ended November 30, 2010			Three Months Ended November 30, 2009
Net loss, as reported	$	(7.6	)	$	(7.2	)
Depreciation		44.7			47.7
Amortization		94.8			95.3
Interest expense		122.9			130.1
Other (income) expense, net		(3.9	)		(10.6	)
Income taxes		(5.6	)		(18.2	)
EBITDA, as reported*	$	245.3		$	237.1

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Other Financial Information

Net Loss to EBITDA, as reported

(in millions, unaudited)

	Six Months Ended November 30, 2010			Six Months Ended November 30, 2009
Net loss, as reported	$	(25.4	)	$	(30.0	)
Depreciation		86.2			89.5
Amortization		190.0			190.1
Interest expense		249.7			261.6
Other (income) expense, net		(5.7	)		(14.9	)
Income taxes		(43.1	)		(43.5	)
EBITDA, as reported*	$	451.7		$	452.8

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Other Financial Information

Operating Income, as reported to EBITDA, as adjusted

(in millions, unaudited)

	Three Months Ended November 30, 2010			Three Months Ended November 30, 2009
Operating income, as reported	$	105.8		$	94.1
Depreciation		44.7			47.7
Amortization		94.8			95.3
EBITDA, as reported*	$	245.3		$	237.1
Special items and purchase accounting adjustments:
Share-based payment		4.3			4.3
Litigation settlements and reserves and other legal fees		3.1			3.5
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)		8.4			17.8
Sponsor fee		2.6			2.7
EBITDA, as adjusted*	$	263.7		$	265.4
Net sales	$	698.3		$	695.6
EBITDA percentage, as reported		35.1	%		34.1	%
EBITDA percentage, as adjusted*		37.8	%		38.2	%

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Other Financial Information

Operating Income, as reported to EBITDA, as adjusted

(in millions, unaudited)

	Six Months Ended November 30, 2010			Six Months Ended November 30, 2009
Operating income, as reported	$	175.5		$	173.2
Depreciation		86.2			89.5
Amortization		190.0			190.1
EBITDA, as reported*	$	451.7		$	452.8
Special items and purchase accounting adjustments:
Share-based payment		9.4			9.5
Litigation settlements and reserves and other legal fees		7.4			5.2
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)		17.7			23.3
Sponsor fee		4.9			4.9
EBITDA, as adjusted*	$	491.1		$	495.7
Net sales	$	1,339.0		$	1,325.7
EBITDA percentage, as reported		33.7	%		34.2	%
EBITDA percentage, as adjusted*		36.7	%		37.4	%

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Reconciliation of GAAP Consolidated Net Loss to

Non-GAAP Adjusted Consolidated Net Income

(in millions, unaudited)

	Three Months Ended November 30, 2010			Three Months Ended November 30, 2009
Net loss, as reported	$	(7.6	)	$	(7.2	)
Purchase accounting depreciation		4.4			4.4
Purchase accounting amortization		92.5			94.3
Share-based payment		4.3			4.3
Litigation settlements and reserves and other legal fees		3.1			3.5
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)		8.4			17.8
Sponsor fee		2.6			2.7
Tax effect on special and purchase accounting items		(41.7	)		(45.0	)
Net income, as adjusted*	$	66.0		$	74.8

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Reconciliation of GAAP Consolidated Net Loss to

Non-GAAP Adjusted Consolidated Net Income

(in millions, unaudited)

	Six Months Ended November 30, 2010			Six Months Ended November 30, 2009
Net loss, as reported	$	(25.4	)	$	(30.0	)
Purchase accounting depreciation		8.8			8.9
Purchase accounting amortization		184.9			188.2
Share-based payment		9.4			9.5
Litigation settlements and reserves and other legal fees		7.4			5.2
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)		17.7			23.3
Sponsor fee		4.9			4.9
Tax effect on special and purchase accounting items		(90.9	)		(86.0	)
Net income, as adjusted*	$	116.8		$	124.0

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Other Financial Information

Senior Secured Leverage Ratio

(in millions, unaudited)

	November 30, 2010			May 31, 2008
Senior Secured Debt:
USD Term Loan B	$	2,269.8		$	2,328.3
EUR Term Loan B		1,119.8			1,355.2
Asset Based Revolver		—			—
Cash Flow Revolvers		—			—
Consolidated Senior Secured Debt		3,389.6	A		3,683.5	F
Senior Notes		2,550.7			2,570.7
European Operations		5.8			46.6
Consolidated Total Debt		5,946.1	C		6,300.8	H
Cash		(228.6	)		(127.6	)
Net Debt*	$	5,717.5	D	$	6,173.2	I
LTM EBITDA*
Quarter 3 Fiscal 2010 EBITDA		250.7
Quarter 4 Fiscal 2010 EBITDA		253.6
Quarter 1 Fiscal 2011 EBITDA		227.4
Quarter 2 Fiscal 2011 EBITDA		263.7
“Run Rate” Cost Savings**		—	E
LTM EBITDA*	$	995.4	B
Quarter 1 Fiscal 2008 EBITDA					180.7
Quarter 2 Fiscal 2008 EBITDA					210.8
Quarter 3 Fiscal 2008 EBITDA					217.1
Quarter 4 Fiscal 2008 EBITDA					220.5
“Run Rate” Cost Savings**					57.0	J
LTM EBITDA*				$	886.1	G
Senior Secured Leverage Ratio		3.41	A / B		4.16	F / G
Total Leverage Ratio		5.97	C / B		7.11	H / G
Total Leverage Ratio (Net Debt)		5.74	D / B		6.97	I / G
Excluding Cost Savings**		5.74	D / (B-E)		7.45	I / (G-J)

* See Non-GAAP Financial Measures Disclosure Above

** As defined by the Credit Agreement dated September 25, 2007

Biomet, Inc.

Balance Sheets

(in millions, unaudited)

	(Preliminary) November 30, 2010		May 31, 2010
Assets
Cash and cash equivalents	$	228.6	$	189.1
Accounts receivable, net		475.4		452.5
Income tax receivable		6.7		19.2
Inventories		571.4		507.3
Current deferred income taxes		56.6		64.3
Prepaid expenses and other		95.3		72.6
Property, plant and equipment, net		636.3		622.0
Intangible assets, net		5,131.6		5,190.3
Goodwill		4,800.8		4,707.5
Other assets		121.1		144.2
Total Assets	$	12,123.8	$	11,969.0
Liabilities and Shareholder’s Equity
Current liabilities	$	472.9	$	482.9
Current portion of long-term debt		36.4		35.6
Long-term debt, net of current portion		5,909.7		5,860.9
Deferred income taxes, long-term		1,648.1		1,674.9
Other long-term liabilities		188.0		181.2
Shareholder’s equity		3,868.7		3,733.5
Total Liabilities and Shareholder’s Equity	$	12,123.8	$	11,969.0
Net Debt (a)*	$	5,717.5	$	5,707.4

(a) Net debt is the sum of total debt less cash and cash equivalents and short-term investments.

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Consolidated Statements of Cash Flows

(in millions, unaudited)

	Fiscal 2011
				(Preliminary)			(Preliminary)
	Three Months Ended			Three Months Ended			Six Months Ended
	August 31, 2010			November 30, 2010			November 30, 2010
CASH FLOWS PROVIDED BY OPERATING ACTIVITIES:
Net loss	$	(17.8	)	$	(7.6	)	$	(25.4	)
Adjustments to reconcile net loss to net cash from operating activities:
Depreciation and amortization		136.7			139.5			276.2
Amortization of deferred financing costs		2.8			2.9			5.7
Stock based compensation expense		5.1			4.3			9.4
Recovery of doubtful accounts receivable		(1.3	)		(0.3	)		(1.6	)
Gain on sale of investments, net		—			(2.6	)		(2.6	)
Provision for inventory obsolescence		1.7			5.3			7.0
Deferred income taxes		(43.8	)		(10.6	)		(54.4	)
Other		0.5			(18.2	)		(17.7	)
Changes in operating assets and liabilities:
Accounts receivable		27.1			(28.6	)		(1.5	)
Inventories		(18.3	)		(33.2	)		(51.5	)
Prepaid expenses		(12.2	)		10.5			(1.7	)
Accounts payable		(0.6	)		3.0			2.4
Income taxes		4.3			2.9			7.2
Accrued interest		67.7			(74.3	)		(6.6	)
Other		(20.6	)		27.1			6.5
Net cash provided by operating activities		131.3			20.1			151.4
CASH FLOWS USED IN INVESTING ACTIVITIES:
Proceeds from sales of investments		3.8			7.9			11.7
Net proceeds from sale of property and equipment		—			4.8			4.8
Capital expenditures		(36.5	)		(52.3	)		(88.8	)
Acquisitions, net of cash acquired		(9.6	)		(6.8	)		(16.4	)
Net cash used in investing activities		(42.3	)		(46.4	)		(88.7	)
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:
Debt:
Proceeds under revolving credit agreements		0.1			—			0.1
Payments under revolving credit agreements		(0.6	)		(0.5	)		(1.1	)
Payments under senior secured credit facility		(8.5	)		(8.7	)		(17.2	)
Repurchases of senior notes		—			(11.2	)		(11.2	)
Equity:
Repurchase of LVB Acquisition, Inc. shares		(0.2	)		(0.8	)		(1.0	)
Net cash provided by (used in) financing activities		(9.2	)		(21.2	)		(30.4	)
Effect of exchange rate changes on cash		5.1			2.1			7.2
Increase (decrease) in cash and cash equivalents		84.9			(45.4	)		39.5
Cash and cash equivalents, beginning of period		189.1			274.0			189.1
Cash and cash equivalents, end of period	$	274.0		$	228.6		$	228.6
Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest	$	56.3		$	194.5		$	250.8
Income taxes	$	6.5		$	11.2		$	17.7

Biomet, Inc.

Consolidated Statements of Cash Flows

(in millions, unaudited)

	Fiscal 2010
	Three Months Ended			Three Months Ended			Six Months Ended
	August 31, 2009			November 30, 2009			November 30, 2009
CASH FLOWS PROVIDED BY OPERATING ACTIVITIES:
Net loss	$	(22.8	)	$	(7.2	)	$	(30.0	)
Adjustments to reconcile net loss to net cash from operating activities:
Depreciation and amortization		136.6			143.0			279.6
Amortization of deferred financing costs		2.8			2.8			5.6
Stock based compensation expense		5.2			4.3			9.5
Recovery of doubtful accounts receivable		(5.2	)		(0.6	)		(5.8	)
Gain on sale of investments, net		(0.8	)		(0.4	)		(1.2	)
Provision for inventory obsolescence		6.5			2.3			8.8
Deferred income taxes		(47.1	)		(30.7	)		(77.8	)
Other		(1.1	)		6.2			5.1
Changes in operating assets and liabilities:
Accounts receivable		19.8			(47.5	)		(27.7	)
Inventories		(22.5	)		(9.4	)		(31.9	)
Prepaid expenses		(4.4	)		(1.8	)		(6.2	)
Accounts payable		(3.0	)		(6.1	)		(9.1	)
Income taxes		14.6			8.3			22.9
Accrued interest		70.0			(70.6	)		(0.6	)
Other		(93.1	)		33.0			(60.1	)
Net cash provided by operating activities		55.5			25.6			81.1
CASH FLOWS USED IN INVESTING ACTIVITIES:
Proceeds from sales of investments		3.4			2.9			6.3
Purchases of investments		(1.8	)		(2.0	)		(3.8	)
Capital expenditures		(53.9	)		(52.1	)		(106.0	)
Acquisitions, net of cash acquired		(2.4	)		(6.6	)		(9.0	)
Net cash used in investing activities		(54.7	)		(57.8	)		(112.5	)
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:
Debt:
Proceeds under revolving credit agreements		20.1			—			20.1
Payments under revolving credit agreements		(1.3	)		(66.7	)		(68.0	)
Payments under senior secured credit facility		(8.9	)		(9.0	)		(17.9	)
Equity:
Repurchase of LVB Acquisition, Inc. shares		(0.6	)		(0.5	)		(1.1	)
Net cash provided by (used in) financing activities		9.3			(76.2	)		(66.9	)
Effect of exchange rate changes on cash		0.7			(0.4	)		0.3
Increase (decrease) in cash and cash equivalents		10.8			(108.8	)		(98.0	)
Cash and cash equivalents, beginning of period		215.6			226.4			215.6
Cash and cash equivalents, end of period	$	226.4		$	117.6		$	117.6
Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest	$	58.9		$	198.2		$	257.1
Income taxes	$	0.8		$	5.6		$	6.4

Biomet, Inc.

Other Financial Information

GAAP Operating Cash Flow Reconciled to Free Cash Flow & Unlevered Free Cash Flow

(in millions, unaudited)

	Fiscal 2011
				(Preliminary)			(Preliminary)
	Three Months Ended			Three Months Ended			Six Months Ended
	August 31, 2010			November 30, 2010			November 30, 2010
Net loss	$	(17.8	)	$	(7.6	)	$	(25.4	)
Adjustments:
Depreciation and amortization		136.7			139.5			276.2
Amortization of deferred financing costs		2.8			2.9			5.7
Stock based compensation expense		5.1			4.3			9.4
Recovery of doubtful accounts receivable		(1.3	)		(0.3	)		(1.6	)
Gain on sale of investments, net		—			(2.6	)		(2.6	)
Provision for inventory obsolescence		1.7			5.3			7.0
Deferred income taxes		(43.8	)		(10.6	)		(54.4	)
Other		0.5			(18.2	)		(17.7	)
TOTAL		83.9			112.7			196.6
Changes In:
Accounts receivables		27.1			(28.6	)		(1.5	)
Inventories		(18.3	)		(33.2	)		(51.5	)
Prepaid expenses		(12.2	)		10.5			(1.7	)
Accounts payable		(0.6	)		3.0			2.4
Income taxes		4.3			2.9			7.2
Accrued Interest		67.7			(74.3	)		(6.6	)
Other		(20.6	)		27.1			6.5
Net cash provided by operating activities	$	131.3		$	20.1		$	151.4
Capital expenditures		(36.5	)		(52.3	)		(88.8	)
Free Cash Flow*	$	94.8		$	(32.2	)	$	62.6
Acquisitions, net of cash acquired		(9.6	)		(6.8	)		(16.4	)
Proceeds from sales of investments		3.8			7.9			11.7
Proceeds from sale of property and equipment		—			4.8			4.8
Loss on bond repurchase		—			(1.2	)		(1.2	)
Repurchase of LVB Acquisition, Inc. shares		(0.2	)		(0.8	)		(1.0	)
Add back: cash paid for interest		56.3			194.5			250.8
Effect of exchange rates on cash		5.1			2.1			7.2
Unlevered Free Cash Flow* (1)	$	150.2		$	168.3		$	318.5

(1) Cash flow that does not take into account the interest payments required on outstanding debt. Commonly used by companies that are highly leveraged to show how assets perform before interest.

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Other Financial Information

GAAP Operating Cash Flow Reconciled to Free Cash Flow & Unlevered Free Cash Flow

(in millions, unaudited)

	Fiscal 2010
	Three Months Ended			Three Months Ended			Six Months Ended
	August 31, 2009			November 30, 2009			November 30, 2009
Net loss	$	(22.8	)	$	(7.2	)	$	(30.0	)
Adjustments:
Depreciation and amortization		136.6			143.0			279.6
Amortization of deferred financing costs		2.8			2.8			5.6
Stock based compensation expense		5.2			4.3			9.5
Recovery of doubtful accounts receivable		(5.2	)		(0.6	)		(5.8	)
Gain on sale of investments, net		(0.8	)		(0.4	)		(1.2	)
Provision for inventory obsolescence		6.5			2.3			8.8
Deferred income taxes		(47.1	)		(30.7	)		(77.8	)
Other		(1.1	)		6.2			5.1
TOTAL		74.1			119.7			193.8
Changes In:
Accounts receivables		19.8			(47.5	)		(27.7	)
Inventories		(22.5	)		(9.4	)		(31.9	)
Prepaid expenses		(4.4	)		(1.8	)		(6.2	)
Accounts payable		(3.0	)		(6.1	)		(9.1	)
Income taxes		14.6			8.3			22.9
Accrued Interest		70.0			(70.6	)		(0.6	)
Other		(93.1	)		33.0			(60.1	)
Net cash provided by operating activities	$	55.5		$	25.6		$	81.1
Capital expenditures		(53.9	)		(52.1	)		(106.0	)
Free Cash Flow*	$	1.6		$	(26.5	)	$	(24.9	)
Acquisitions, net of cash acquired		(2.4	)		(6.6	)		(9.0	)
Proceeds from sales of investments		3.4			2.9			6.3
Purchases of investments		(1.8	)		(2.0	)		(3.8	)
Repurchase of LVB Acquisition, Inc. shares		(0.6	)		(0.5	)		(1.1	)
Add back: cash paid for interest		58.9			198.2			257.1
Effect of exchange rates on cash		0.7			(0.4	)		0.3
Unlevered Free Cash Flow* (1)	$	59.8		$	165.1		$	224.9

(1) Cash flow that does not take into account the interest payments required on outstanding debt. Commonly used by companies that are highly leveraged to show how assets perform before interest.

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Other Financial Information

Gross Profit, as reported to Gross Profit, as adjusted

(in millions, unaudited)

	Three Months Ended November 30, 2010			Three Months Ended November 30, 2009
Gross profit, as reported	$	490.8		$	482.0
Purchase accounting depreciation		4.4			4.4
Share-based payment		0.3			0.5
Litigation settlements and reserves and other legal fees		—			(1.1	)
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)		5.7			12.7
Gross profit, as adjusted*	$	501.2		$	498.5
Net sales	$	698.3		$	695.6
Gross profit percentage, as reported		70.3	%		69.3	%
Gross profit percentage, as adjusted*		71.8	%		71.7	%

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Other Financial Information

Gross Profit, as reported to Gross Profit, as adjusted

(in millions, unaudited)

	Six Months Ended November 30, 2010			Six Months Ended November 30, 2009
Gross profit, as reported	$	937.5		$	926.8
Purchase accounting depreciation		8.8			8.9
Share-based payment		0.6			0.9
Litigation settlements and reserves and other legal fees		—			(1.1	)
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)		12.5			15.6
Gross profit, as adjusted*	$	959.4		$	951.1
Net sales	$	1,339.0		$	1,325.7
Gross profit percentage, as reported		70.0	%		69.9	%
Gross profit percentage, as adjusted*		71.7	%		71.7	%

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Other Financial Information

Selling, General and Administrative Expense, as reported to Selling, General and Administrative Expense, as adjusted

(in millions, unaudited)

	Three Months Ended November 30, 2010			Three Months Ended November 30, 2009
Selling, general and administrative expense, as reported	$	260.6		$	267.4
Share-based payment		(3.6	)		(3.2	)
Litigation settlements and reserves and other legal fees		(3.1	)		(5.7	)
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, and other related costs)		(2.2	)		(4.9	)
Sponsor fee		(2.6	)		(2.7	)
Selling, general and administrative expense, as adjusted*	$	249.1		$	250.9
Net sales	$	698.3		$	695.6
SG&A as a percent of sales, as reported		37.3	%		38.4	%
SG&A as a percent of sales, as adjusted*		35.7	%		36.1	%

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Other Financial Information

Selling, General and Administrative Expense, as reported to Selling, General and Administrative Expense, as adjusted

(in millions, unaudited)

	Six Months Ended November 30, 2010			Six Months Ended November 30, 2009
Selling, general and administrative expense, as reported	$	512.5		$	513.4
Share-based payment		(7.8	)		(7.4	)
Litigation settlements and reserves and other legal fees		(7.4	)		(7.4	)
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, and other related costs)		(4.3	)		(7.5	)
Sponsor fee		(4.9	)		(4.9	)
Selling, general and administrative expense, as adjusted*	$	488.1		$	486.2
Net sales	$	1,339.0		$	1,325.7
SG&A as a percent of sales, as reported		38.3	%		38.7	%
SG&A as a percent of sales, as adjusted*		36.5	%		36.7	%

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Other Financial Information

Research and Development Expense, as reported to Research and Development Expense, as adjusted

(in millions, unaudited)

	Three Months Ended November 30, 2010			Three Months Ended November 30, 2009
Research and development expense, as reported	$	29.6		$	25.2
Share-based payment		(0.4	)		(0.6	)
Litigation settlements and reserves and other legal fees		—			1.1
Operational restructuring and consulting expenses related to operational initiatives (severance, and other related costs)		(0.5	)		(0.2	)
Research and development expense, as adjusted*	$	28.7		$	25.5
Net sales	$	698.3		$	695.6
R&D as a percent of sales, as reported		4.2	%		3.6	%
R&D as a percent of sales, as adjusted*		4.1	%		3.7	%

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Other Financial Information

Research and Development Expense, as reported to Research and Development Expense, as adjusted

(in millions, unaudited)

	Six Months Ended November 30, 2010			Six Months Ended November 30, 2009
Research and development expense, as reported	$	59.5		$	50.1
Share-based payment		(1.0	)		(1.2	)
Litigation settlements and reserves and other legal fees		—			1.1
Operational restructuring and consulting expenses related to operational initiatives (severance, and other related costs)		(0.9	)		(0.2	)
Research and development expense, as adjusted*	$	57.6		$	49.8
Net sales	$	1,339.0		$	1,325.7
R&D as a percent of sales, as reported		4.4	%		3.8	%
R&D as a percent of sales, as adjusted*		4.3	%		3.8	%

* See Non-GAAP Financial Measures Disclosure Above